Current situation and future development trend of

2022-09-21
  • Detail

The current situation and future development trend of flexible packaging infusion bags in China (2)

the production cost of flexible packaging infusion bags is high

there are too many imported equipment for the production of flexible packaging infusion bags, with large one-time investment and high depreciation. However, due to the development of domestic packaging equipment industry in recent years, this situation has improved. The investment in basic equipment has been reduced to more than half of the original, which is also an opportunity for soft packaging and soft infusion in China. In addition, the geological grade medical particles of packaging materials, non PVC barrel films, film films, mouth tubes, color bands, plastic covers, etc. all need to be imported, which virtually increases the production cost of enterprises

there is no support of high-quality new drugs for flexible packaging infusion

more than 90% of the currently listed flexible packaging infusion are common liquids, namely glucose, sodium chloride, etc. Although many project units mentioned the production of new varieties of concern, such as therapeutic infusion, etc. in the project approval and research and development stages, the actual situation is far from that. The ultimate way for light plastic infusion enterprises to make profits depends on expanding production scale and high-quality products. If there are no high-quality products, the current high selling price is only a short-term benefit. With the increase of the introduction of flexible packaging infusion manufacturers, there may be a soft plastic infusion war in the future

market problems

are mainly reflected in the infusion price and nurses' medication habits. Domestic glass bottle infusion accounts for more than 95% of the total market, and the price has an absolute advantage. However, due to some characteristics of soft bag infusion itself, it is being accepted by the majority of patients and hospitals. It is believed that in the near future, with the decline of cost, soft bag infusion and glass bottle will share the world equally or even catch up with the Ministry. Over time, the market should not be the main problem

therapeutic infusion of more than 100ml was not selected from the medical insurance catalogue

in the research of therapeutic infusion, the infusion enterprises formed a patent protection group, and the determination of the specification was designed with reference to the foreign Pharmacopoeia, when P increased to 4kn, write down the F value or the usage and dosage in the national clinical medication instructions, and there will be products with specifications of 1 ooml, 250ml and 500ml. If the infusion products with a specification of more than 1 ooml can not enter the medical insurance catalogue, what is the recommendation and rationality of the national drug instructions? If this great situation is irreversible or will be improved, some infusion enterprises can only shift their production focus from infusion to other medical insurance dosage forms, and the R & D investment of several million yuan in therapeutic infusion is not a small amount for any enterprise. If the industry is generally profitable and faces the problems of medical insurance and pricing, the development of enterprises will indeed encounter great problems, This has a far more serious impact on the large infusion industry, especially the soft bag infusion

the future development trend of flexible packaging infusion

the development of polyolefin multi-layer coextrusion film

the development of polyolefin multi-layer coextrusion film has experienced two stages. One is the polyolefin composite film from the 1980s to the 1990s, but due to the use of adhesives in the production process, adhesives also have a potential impact on the stability of the drug solution. The second stage is the polyolefin multi-layer coextrusion film developed in the past four or five years, Without using adhesives in the production process, multi-layer polyolefin materials are melted, crosslinked and coextruded at the same time, which not only eliminates the instability caused by adhesives, but also increases the performance of membrane materials, making them safer and more effective, meeting the requirements of medicine and environmental protection. It is the development direction of infusion packaging materials. In order to distinguish from the original PVC infusion film, we collectively call this polyolefin multilayer coextrusion film non PVC infusion film

polyolefin duoyueqi extrusion film production materials have strict pharmaceutical quality standards. The production is carried out under the condition of 10000 grade cleanliness. In the production process, no adhesive and plasticizer are used, and 100 grade filtered air is used to blow the film. The cylindrical abdomen is always kept closed, avoiding pollution. At present, the popular polyoxymethylene multilayer coextrusion membrane has 3-layer and 5-layer structures, and most of them use modified polypropylene as the main material of each layer through the visit to the industrial base of copper based new materials.

makes the membrane material have good heat sealing, permeability resistance and elasticity. Lianyungang Zhongjin pharmaceutical packaging Co., Ltd. in China has recently launched a co extruded film with polypropylene for three Tudu, filling the gap in China

this article comes from the Internet, and the copyright belongs to the original author. It is only for everyone to share and learn. If the author believes that infringement is involved, please contact us, and we will delete it immediately after the fourth verification

Copyright © 2011 JIN SHI